If a Lyme disease vaccine gets approved, how would it go over? We asked hunters
As Pfizer and Valneva prepare to seek approval for a new Lyme disease vaccine, experts are questioning whether it will face public resistance. Hunters, who are at high risk for tick-borne illnesses, are being surveyed to gauge potential vaccine uptake in rural, conservative populations.
Why it matters
Understanding vaccine hesitancy in high-risk groups is critical for public health strategies, especially as climate change increases the prevalence of tick-borne diseases.
It's tick season, possibly the worst in a decade .
The article acknowledges political demographics but frames the issue around public health and vaccine skepticism rather than taking a political side.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in